Supernus, Inc. SUPN
29.20 USD -0.25 (-0.85%)
At closeNov 12, 2026, 4:52 PM EST
29.39 +0.19 +0.65%
After hours · Nov 12, 4:52 PM ET
28.79 Day range 30.17
25.92 52-week range 42.81
- YTD
- -18.62%
- 1 year
- -2.99%
News
globenewswire.com Supernus, Inc. to Participate in the 2026 Jefferies Global Healthcare Conference in London ROCKVILLE, Md., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Supernus, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous…
benzinga.com This Supernus Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings…
benzinga.com This Supernus Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday Analysts initiated bullish coverage on IAM, AMRO, CWH, SUPN, issuing Buy, Outperform or Overweight ratings with price targets.
benzinga.com B of A Securities Initiates Coverage On Supernus with Buy Rating, Announces Price Target of $47 B of A Securities analyst Chi Fong initiates coverage on Supernus (NASDAQ:SUPN) with a Buy rating and announces Price Target of $47.
defenseworld.net Head-To-Head Review: Supernus Pharmaceuticals (NASDAQ:SUPN) and Chugai Pharmaceutical (OTCMKTS:CHGCY) Chugai Pharmaceutical (OTCMKTS:CHGCY - Get Free Report) and Supernus Pharmaceuticals (NASDAQ: SUPN - Get Free Report) are both healthcare companies, but which is the better stock? We will contrast…
benzinga.com Piper Sandler Reinstates Overweight on Supernus, Announces $47 Price Target Piper Sandler analyst David Amsellem reinstates Supernus (NASDAQ:SUPN) with a Overweight and announces $47 price target.
benzinga.com Block To Rally Around 54%? Here Are 10 Top Analyst Forecasts For Wednesday Analysts raised targets for FRSH, EW, ATRC, SUPN and DUOL; cut targets for FLG and AMD. EW was upgraded, while FLG was downgraded.
benzinga.com Cantor Fitzgerald Maintains Overweight on Supernus, Raises Price Target to $87 Cantor Fitzgerald analyst Kristen Kluska maintains Supernus (NASDAQ:SUPN) with a Overweight and raises the price target from $67 to $87.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Curis (NASDAQ:CRIS) stock increased by 25.6% to $0.83 during Tuesday's regular session. The company's market cap stands at $1.6 million. Pasithea Therapeutics (NASDAQ:KTTA) shares increased…
benzinga.com Supernus Pharmaceuticals Q3 2026 Earnings Call Transcript Supernus Pharmaceuticals (NASDAQ:SUPN) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
benzinga.com Supernus Pharmaceuticals Raises FY2026 Sales Guidance from $860.000M-$890.000M to $875.000M-$900.000M vs $877.738M Est Supernus Pharmaceuticals (NASDAQ:SUPN) raises FY2026 sales outlook from $860.000 million-$890.000 million to $875.000 million-$900.000 million vs $877.738 million estimate.- benzinga.com Supernus Pharmaceuticals Q3 EPS $0.35 Beats $0.02 Estimate, Sales $226.771M Beat $215.917M Estimate Supernus Pharmaceuticals (NASDAQ:SUPN) reported quarterly earnings of $0.35 per share which beat the analyst consensus estimate of $0.02 by 1650 percent. This is a 143.75 percent increase over losses…
benzinga.com MSG Rangers To Replace Arbor Realty Trust In The S&P SmallCap 600 Effective On October 27; Huron Consulting Group To Replace Supernus Pharmaceuticals In The S&P SmallCap 600 Effective Prior To The Opening Of Trading On Monday, November 2 https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20261022-1485639/1485639_msgs-supn-6.pdf- benzinga.com Reported Earlier, Supernus Secures Seven Years Of FDA Orphan-Drug Exclusivity For ONAPGO, Seeks Second Supplier Approval By Mid-2027 Orphan-drug exclusivity provides seven years of market exclusivity for ONAPGOAdditionally, the Company submitted an sNDA to the FDA for a second supplier for ONAPGO, with potential approval by…
benzinga.com Supernus Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript Supernus Pharmaceuticals (NASDAQ:SUPN) held its second-quarter earnings conference call on Tuesday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs.…
benzinga.com Top 3 Health Care Stocks You'll Regret Missing This Quarter The most oversold health care stocks present a buying opportunity. RSI indicator compares stock strength on up and down days, indicating short-term performance. Here's the latest list of oversold…
benzinga.com Supernus to Combine with Indivior To Form CNS Biopharmaceutical Leader with Potential $2 Billion in Revenue Supernus and Indivior agree to merge in an all-stock deal, targeting $2.2 billion in revenue and $125 million in synergies.
benzinga.com UPDATE: Supernus Pharmaceuticals Q2 Adj. EPS $0.53 Beats $0.42 Estimate Supernus Pharmaceuticals (NASDAQ:SUPN) reported quarterly earnings of $0.53 per share which beat the analyst consensus estimate of $0.42 by 26.19 percent. This is a 32.5 percent increase over…
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock increased by 121.2% to $6.99 during Monday's pre-market session. The market value of their outstanding shares is at $2.0 million. Supernus…- benzinga.com Supernus Pharmaceuticals To Merge With Indivior Pharmaceuticals; SUPN Stockholders Will Receive 1.5401 Shares Of INDV Per SUPN Share; Indivior Stockholders Will Receive One-Time Special Cash Dividend Of $1B Immediately Prior To Closing; Expected To Generate $125M In Annual Cost Synergies Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) and Indivior Pharmaceuticals, Inc. (NASDAQ:INDV) today announced that they have entered into a definitive agreement to combine in a tax-free all-stock…
benzinga.com Cantor Fitzgerald Maintains Overweight on Supernus Pharmaceuticals, Raises Price Target to $67 Cantor Fitzgerald analyst Kristen Kluska maintains Supernus Pharmaceuticals (NASDAQ:SUPN) with a Overweight and raises the price target from $63 to $67.
benzinga.com Supernus Pharmaceuticals Q1 2026 Earnings Call Transcript 
benzinga.com Earnings Scheduled For May 5, 2026 - benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com Earnings Scheduled For February 24, 2026
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com Earnings Scheduled For November 4, 2025 - benzinga.com 10 Health Care Stocks Whale Activity In Today's Session
benzinga.com Crowdstrike To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Thursday - benzinga.com Earnings Scheduled For August 5, 2025
benzinga.com Earnings Scheduled For May 6, 2025 - benzinga.com Earnings Scheduled For February 25, 2025
benzinga.com This Workday Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday 
benzinga.com Gentherm Posts Downbeat Results, Joins Celanese, Bumble And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session 
benzinga.com Why Global Blue Group Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket - benzinga.com This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday
- benzinga.com Earnings Scheduled For February 27, 2024 Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million.
- benzinga.com Earnings Scheduled For November 8, 2023 Companies Reporting Before The Bell • Flex LNG (NYSE:FLNG) is estimated to report earnings for its third quarter.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 647 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 369 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday During the session on Thursday, 461 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday During Tuesday's session, 275 companies made new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday Friday's session saw 169 companies set new 52-week lows.
- benzinga.com Earnings Scheduled For August 8, 2023 Companies Reporting Before The Bell • Warner Music Gr (NASDAQ:WMG) is likely to report quarterly earnings at $0.21 per share on revenue of $1.48 billion.
- benzinga.com Earnings Scheduled For May 9, 2023 Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.17 per share on revenue of $440.16 million.
- benzinga.com Earnings Scheduled For February 28, 2023 Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report earnings for its fourth quarter.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday During Thursday's session, 108 stocks hit new 52-week highs.
- benzinga.com Earnings Scheduled For August 4, 2022 Companies Reporting Before The Bell • Toyota Motor (NYSE:TM) is projected to report earnings for its first quarter.
- benzinga.com Earnings Scheduled For February 28, 2022 Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter.
- benzinga.com Earnings Scheduled For November 3, 2021 Companies Reporting Before The Bell • R.R.Donnelley & Sons (NYSE:RRD) is likely to report quarterly earnings at $0.32 per share on revenue of $1.19 billion.